Bifidobacteria-derived lipoproteins inhibit infection with coxsackievirus b4 in vitro

Highlights • Bifidobacteria secreting lipoproteins protect HEp-2 cell against coxsackievirus B4. • Antiviral activity is supported by the secreted lipoprotein aggregates (LpAs). • Antiviral activity relies on the hydrophobic protein from LpAs. • Proteins from LpAs align with the viral north rim foot...

Full description

Saved in:
Bibliographic Details
Published in:International journal of antimicrobial agents 2017-08, Vol.50 (2), p.177-185
Main Authors: Kfoury, Khalil Antoine EL, Romond, Marie-Bénédicte, Scuotto, Angelo, Alidjinou, Enagnon Kazali, Dabboussi, Fouad, Hamze, Monzer, Engelmann, Ilka, Sane, Famara, Hober, Didier
Format: Article
Language:English
Subjects:
Antiviral Agents - chemistry
Antiviral Agents - metabolism
Bacterial Proteins - chemistry
Bacterial Proteins - metabolism
Bifidobacteria
Bifidobacterium breve - metabolism
Bifidobacterium longum - metabolism
Cell Line
Coxsackievirus B4
Coxsackievirus Infections - prevention & control
Diabetes type 1
Enterovirus
Enterovirus B, Human - drug effects
Humans
Infectious Disease
Lipoprotein
Lipoproteins - chemistry
Lipoproteins - metabolism
Molecular Docking Simulation
Prevention
Protein Binding
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Highlights • Bifidobacteria secreting lipoproteins protect HEp-2 cell against coxsackievirus B4. • Antiviral activity is supported by the secreted lipoprotein aggregates (LpAs). • Antiviral activity relies on the hydrophobic protein from LpAs. • Proteins from LpAs align with the viral north rim footprint onto CAR sequence. • LpA sequences form hydrogen bonds with viral residues involved in CAR binding.
ISSN:0924-8579
1872-7913
DOI:10.1016/j.ijantimicag.2017.03.010